Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

Market Checkup: An In-Depth Look at Bristol-Myers Squibb

A close look at pharmaceutical company Bristol-Myers Squibb's last quarter, upcoming catalysts, and reasons to buy and sell the stock.

In this edition of The Motley Fool's health-care show Market Checkup, health-care analysts David Williamson and Max Macaluso take a close look at one of the largest pharmaceutical companies in the world: Bristol-Myers Squibb. This drugmaker posted results in line with analyst estimates last quarter, but what was behind it's massive year-over-year decline in revenue? What are the reasons to buy and sell this stock today? What should investors be watching in upcoming quarters? Watch today's show to find out what our analysts think.

Author

Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo